Get the Stockscreener App
37.05
2.27%
-0.90
Newamsterdam Pharma Company Nv stock is traded at $37.05, with a volume of 495.22K.
It is down -2.27% in the last 24 hours and up +20.93% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$37.95
Open:
$37.65
24h Volume:
495.22K
Relative Volume:
0.49
Market Cap:
$4.18B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-17.23
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
+2.91%
1M Performance:
+20.93%
6M Performance:
+85.16%
1Y Performance:
+108.13%
1-Day Range:
$36.30
$37.99
1-Week Range:
$35.50
$39.03
52-Week Range:
$14.06
$41.47
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
37.08 | 4.27B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.57 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.26 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.88 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.63 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.31 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investors2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownInflation Watch & Real-Time Chart Pattern Alerts - newser.com
Assessing NewAmsterdam Pharma (NasdaqGM:NAMS) Valuation Ahead of Major Phase 3 Data Presentations - simplywall.st
How to escape a deep drawdown in NewAmsterdam Pharma Company N.V.Weekly Risk Report & Community Consensus Trade Signals - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correctionMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Why NewAmsterdam Pharma Company N.V. stock is seen as undervaluedMarket Movers & AI Enhanced Execution Alerts - newser.com
Can NewAmsterdam Pharma Company N.V. (KH6) stock surprise markets with earningsWall Street Watch & Low Drawdown Trading Strategies - newser.com
Is NewAmsterdam Pharma Company N.V. stock poised for growthPortfolio Update Summary & Weekly High Return Forecasts - newser.com
Using economic indicators to assess NewAmsterdam Pharma Company N.V. Equity Warrant potentialJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
Can technical indicators confirm NewAmsterdam Pharma Company N.V. Equity Warrant’s reversalWeekly Trend Summary & Low Risk Entry Point Guides - newser.com
How hedge fund analytics apply to NewAmsterdam Pharma Company N.V. stock2025 Valuation Update & High Conviction Buy Zone Alerts - newser.com
Will earnings trigger a reversal in NewAmsterdam Pharma Company N.V. Equity WarrantJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock reacts to oil pricesExit Point & Long Hold Capital Preservation Plans - newser.com
Pattern recognition hints at NewAmsterdam Pharma Company N.V. upsideMarket Activity Recap & Daily Technical Forecast Reports - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock maintain momentum in 2025Share Buyback & Technical Entry and Exit Tips - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock trading at a premium valuationJuly 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock compares to market leadersEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Can volume confirm reversal in NewAmsterdam Pharma Company N.V. Equity WarrantMarket Rally & Community Verified Watchlist Alerts - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockWeekly Market Report & Community Consensus Picks - newser.com
Risk adjusted return profile for NewAmsterdam Pharma Company N.V. Equity Warrant analyzed2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Key resistance and support levels for NewAmsterdam Pharma Company N.V.July 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Using data models to predict NewAmsterdam Pharma Company N.V. Equity Warrant stock movement2025 Top Decliners & AI Driven Stock Reports - newser.com
Why retail investors pile into NewAmsterdam Pharma Company N.V. Equity Warrant stock2025 Year in Review & Free Community Consensus Stock Picks - newser.com
NewAmsterdam Pharma Hits Day High with 8.05% Surge, Strong Intraday Performance - Markets Mojo
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock bottoming outBuy Signal & Fast Moving Stock Watchlists - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Published on: 2025-11-02 01:19:15 - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock prepared for digital transitionQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
How to build a custom watchlist for NewAmsterdam Pharma Company N.V.Earnings Miss & Daily Entry Point Alerts - newser.com
NewAmsterdam Pharma (NAMS) Is Up 6.2% After Announcing Key Phase 3 Data Reveal at AHA 2025—Has The Bull Case Changed? - simplywall.st
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yieldPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):